Shelter Pharma Ltd. · BSE:SHELTER
Shelter Pharma — H2 FY2026 Earnings Presentation
21 slides from Shelter Pharma's earnings presentation, Jun 17, 2026
Slide 1: BSE submission letter for investor presentation
To, BSE Limited, Floor 25, P J Towers, Dalal Street, Mumbai – 400001 Script Code: 543963 Subject: Submission of Investor Presentation for H2 & FY2026 - Investor Conference Call. Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201
Slide 2: Investor Presentation H2 & FY25-26
I N V E S T O R P R E S E N TA T I O N H2 & FY25-26 Shelter Pharma Limited Redefining Healthcare Through Innovation, Quality, and Sustainable Growth
Slide 3: Safe Harbor
Safe Harbor This presentation is for information purposes only and does not constitute an offer or solicitation to buy or sell securities of Sheltar Pharma Ltd. Information contained herein has been obtained from sources believed to be reliable; however, no representation or warranty is made regardi
Slide 4: Index
Index 01 Company Overview 02 Management Team Who we are Leadership & Experience 03 Product Portfolio 04 Investment Highlights Key Products & Offerings Why Shelter Pharma? 05 Shelter Pharma Vision 2030 06 Financial Highlights Transformation & Growth Journey Financial Performance
Slide 5: Company Overview
COMPANY OVERVIEW ® Shelter
Slide 6: Pharmaceutical & Healthcare Solutions Company
Pharmaceutical & Healthcare Solutions Company India's Emerging Human and Veterinary Healthcare Company Established in 1965, Shelter Pharma has over six decades of experience in natural healthcare and wellness. The Company is committed to delivering safe, effective, and affordable herbal solutions th
Slide 7: Journey & Milestones
Journey & Milestones From a legacy of care to a future of global wellness - Our journey in Human & Veterinary Heaithcare continues. Trusted 1965 1968 1976 Legacy of Healing: In 1968, Shelter Pharma expanded Top brands like Sherolax, Dia Dys, The Foundation of its vision by launching the Animal Diabe
Slide 8: Global Reach. Trusted Medicines. Better Health.
Global Reach. Trusted Medicines. Better Health. PAN INDIA GLOBAL Presence Presence Proudly Supplying ACROSS INDIA Serving healthcare across every state BANGLADESH | UAE | IRAQ | YEMEN | EGYPT | KUWAIT | SUDAN | UK
Slide 9: Leadership & Management
LEADERSHIP & MANAGEMENT MUSTAQIM SHAKEEL Sabugar PROMOTER Sabugar Promoter & WTD Founder Family Promoter & Whole Time Director Managing Director Dedicated new leadership with drive of innovation / 30+ years of visionary excellence leadership in the pharma sector, driving growth, Guiding the future i
Slide 10: Product Portfolio
Product Portfolio Quality. Innovation. Care. Delivering effective healthcare solutions for healthier lives and stronger communities.
Slide 11: Human Product Portfolio
Human Product Portfolio Comprehensive Portfolio of Ayurvedic, Herbal & Human Healthcare Solutions Human Products Sherolax Sheltidin Livodin-12 Happy Forte Gynoshel Gasoshel Tablets Cough Syrup Syrup Capsule Liquid Tablet Diabetone Cocoment B-Kleen Bipinyl Banotone Baldeepak Tablet Ointment Liquid Ca
Slide 12: Veterinary Product Portfolio
Veterinary Product Portfolio Comprehensive Portfolio of Veterinary & Animal Healthcare Solutions Veterinary Products Kafol Mixture Feedmin Regulin Utrona Immuno-UP NKG Forte Bolus Bolus Bolus Liquid Gout Care Multi-Tox Plus Lactona Shelodex Multina VYMET Anical Liquid Bolus Ultra Liquid Oral Oral Tr
Slide 13: Manufacturing Capacity
MANUFACTURING CAPACITY SINGLE SHIFT | PER ANNUM TABLETS LIQUID POWDER CAPSULE OINTMENT 35,80,00,000 8,41,000 9,60,000 2,40,00,000 1,08,000 Nos. Litres kg Nos. kg MAXIMUM CAPACITY
Slide 14: Investment Highlights: Why Shelter Pharma?
INVESTMENT HIGHLIGHTS Why Shelter Pharma? Legacy & Trust Diversified Ayurveda & Strong Manufacturing High Growth Financial Since 1965 Product Portfolio Innovation Driven & Quality Standards Performance 60+ Years of Experience 300+ Products Combining Ayurveda with GMP Certified Consistent Revenue Gro
Slide 15: Shelter Pharma Vision 2030
Shelter Pharma Vision 2030 Innovate | Expand | Excel Innovation And Product Development Shelter Pharma Ltd continues to focus aggressively on innovation and product development, with ongoing investments in advanced formulations, research -driven healthcare solutions, and modern nutraceutical technol
Slide 16: Vision 2030: ₹200 Crore Revenue Target
Shelter Pharma Vision 2030 Innovate | Expand | Excel New Product Launched The company is also preparing to launch a new range of high-value nutraceutical and herbal healthcare products using advanced technologies and innovative formulations, further strengthening its presence in premium wellness and
Slide 17: H2 of FY26 Performance
Performance H2 OF FY26 PERFORMANCE Revenue From EBITDA PAT Operations 39.84 ₹ CRORE 6.47 ₹ CRORE 4.53 ₹ CRORE
Slide 18: Financial Highlights: Almost Debt-Free
Financial Highlights Strong growth. Improving profitability. Debt-light balance sheet. 12 100 73.13 10 9.03 80 8 7.24 60 50.66 6.20 6 40.02 40 4 20 2 0 0 FY24 FY25 FY26 FY24 FY25 FY26 REVENUE FROM OPERATIONS (₹Crore) NET PROFIT (₹Crore) Key Financial Takeaways Revenue Growth 44.35% 15% 26.04% 19.39%
Slide 19: Financial Highlights
Financial Highlights PARTICULARS (₹Crore) FY24 FY25 FY26 3 YEARS CAGR/TRACK RECORD Revenue from Operations 40.02 50.66 73.13 Revenue Growth (3 Years Compounded): 26% EBITDA 8.58 10.07 12.72 EBITDA Margin (%) 21.44% 19.88% 17.39% Net Profit (PAT) 6.20 7.24 9.03 PAT Growth (3 Years Compounded): 15% Ne
Slide 20: Income Statement and Balance Sheet
Financial Highlights Income Statement Balance Sheet (Yearly) Particulars Mar’25 Mar’26 YOY % Growth Particulars Mar’25 Mar’26 YOY % Growth Revenue from Equity & Liabilities operations 50.66 73.13 44.35% Total Expense 40.59 60.41 Equity Capital 11.56 16.61 43.69% EBITDA 10.07 12.72 Reserves 31.16 60.
Slide 21: Thank You
Investor relations advisors FINANCIAL MINDSS (A JaiBharti Group Co. ) SHELTER PHARMA LIMITED HUMAN & VETERINARY HEALTHCARE CA CS LLB Praveen Ranjan CS Aarefa Kutub Kapasi +91 9967487950 [email protected] [email protected] k You